BioTork Competitors

Amyris is a vertically integrated biomanufacturing company that creates specialty molecules for a range of industries, including flavors and fragrances, advanced materials, beauty and personal care, food, and more. Using advanced fermentation technology, Amyris customizes, creates, and manufactures ingredients that enhance lives, protect ecosystems, and take products to the next level of performance. Amyris was founded in 2003 with a bold humanitarian vision to transform access to a lifesaving antimalarial compound using biotechnology. Now, with over two decades of proven commercial success, our proprietary platform is redefining the precision, consistency, and sustainability that is possible with renewable biological chemistry.

Our way of life is built on carbon, from our fuel sources to the materials in our consumer products, but we need a more sustainable way to source it to protect the future of our planet. LanzaTech Global, Inc. is the carbon recycling company transforming waste carbon into sustainable raw materials for everyday products. Using its biorecycling technology, LanzaTech captures carbon-rich gases generated by energy-intensive industries at the source, preventing them from being emitted into the air. LanzaTech then gives that captured carbon a new life as a sustainable replacement for virgin fossil carbon in everything from household cleaners and clothing fibers to packaging and fuels. By partnering with companies across the global supply chain like ArcelorMittal, Zara, H&M Move and Coty, LanzaTech is paving the way for a circular carbon economy.

Caribou Biosciences is a leading clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our next-generation genome-editing technology enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. We believe the future of cell therapy is off-the-shelf, and we are advancing our pipeline of off-the-shelf, or allogeneic, cell therapies from our CAR-T cell therapy platform as readily available treatments for patients with hematologic malignancies and autoimmune diseases.